Breaking News

Yesterday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
On The Fly	Fly Insider: Enviva, Diodes among week's notable insider trades » 15:31 05/30/23 05/30 15:31 05/30/23 15:31 ACAD Acadia Pharmaceuticals $23.73 / -1.055 (-4.26%) , SWX Southwest Gas $58.69 / +0.385 (+0.66%) , MODG Topgolf Callaway $17.28 / +0.155 (+0.91%) , EVA Enviva $8.88 / +0.33 (+3.86%) , ALGT Allegiant Travel $98.73 / -1.01 (-1.01%) , APTV Aptiv $90.97 / -1.17 (-1.27%) , BLNK Blink Charging $6.88 / -0.01 (-0.15%) , DIOD Diodes $92.29 / -3.63 (-3.78%) Welcome to "Fly Insider,"… Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options SWX MODG EVA BLNK APTV ALGT ACAD SWX Southwest Gas $58.69 / +0.385 (+0.66%) 05/15/23 Icahn bought Illumina in Q1, sold shares of Herc and Newell 03/28/23 Carl Icahn increases stake in Southwest Gas by $18.5M 03/23/23 Carl Icahn increases stake in Southwest Gas by $31.6M 03/14/23 Carl Icahn increases stake in Southwest Gas by $32M MODG Topgolf Callaway $17.28 / +0.155 (+0.91%) 05/22/23 Topgolf Callaway exec buys $113.6K in common stock 05/09/23 Topgolf Callaway CEO says FY23 guidance cut reflects near-term volatility 05/09/23 Topgolf Callaway falls 8% to $19.90 after cutting FY23 EPS outlook 01/06/23 Callaway Golf, Stephen Curry enter multi-year partnership extension EVA Enviva $8.88 / +0.33 (+3.86%) 05/08/23 Enviva rises 18.6% 05/05/23 Enviva rises 27.9% 05/04/23 Enviva falls -62.9% 05/04/23 Enviva trading resumes BLNK Blink Charging $6.88 / -0.01 (-0.15%) 05/16/23 Blink Charging commissions first battery to store energized DC 05/15/23 Blink Charging names Ritsaart van Montfrans as Chairman of the Board 05/05/23 Blink Charging partners with Amerit Fleet Solutions for maintenance support 05/03/23 Blink Charging names Brendan Jones as CEO APTV Aptiv $90.97 / -1.17 (-1.27%) 05/15/23 Appaloosa takes stake in FedEx, exits Aptiv 02/14/23 Appaloosa takes stake in Disney, exits position in Mosaic 12/23/22 Aptiv completes acquisition of Wind River from TPG 12/15/22 Aptiv appoints Benjamin Lyon as CTO ALGT Allegiant Travel $98.73 / -1.01 (-1.01%) 05/04/23 Allegiant Travel reaches agreement on a two-year extension with IBT 05/03/23 Allegiant raises FY23 EPS view for airline only to $9.00-$13.00 from $5.00-$9.00 04/13/23 Allegiant Travel reports March 2023 total system passengers up 0.7% y-o-y 03/17/23 Allegiant Travel reports February scheduled service passengers up 13% ACAD Acadia Pharmaceuticals $23.73 / -1.055 (-4.26%) 03/12/23 Acadia Pharmaceuticals announces FDA approval of DAYBUE for Rett syndrome ACAD SWX MODG EVA ALGT APTV BLNK DIOD ACAD Acadia Pharmaceuticals $23.73 / -1.055 (-4.26%) 05/22/23 BofA Acadia Pharmaceuticals price target raised to $26 from $23 at BofA 05/09/23 JMP Securities Acadia Pharmaceuticals price target raised to $23 from $22 at JMP Securities 05/09/23 Citi Acadia Pharmaceuticals price target raised to $21.60 from $21 at Citi SWX Southwest Gas $58.69 / +0.385 (+0.66%) 02/07/23 JPMorgan Southwest Gas price target lowered to $75 from $78 at JPMorgan 12/14/22 Wells Fargo Southwest Gas price target raised to $73 from $66 at Wells Fargo 11/30/22 BofA Southwest Gas downgraded to Neutral at BofA as strategic review 'drags on' 11/30/22 BofA Southwest Gas downgraded to Neutral from Buy at BofA MODG Topgolf Callaway $17.28 / +0.155 (+0.91%) 05/24/23 TD Cowen Topgolf Callaway price target lowered to $18 from $20 at TD Cowen 05/18/23 Compass Point Topgolf Callaway price target lowered to $34 from $37 at Compass Point 04/18/23 KeyBanc Topgolf Callaway coverage transitioned with an Overweight at KeyBanc 04/10/23 Jefferies Market 'yet to fully appreciate' Topgolf Callaway transformation, says Jefferies EVA Enviva $8.88 / +0.33 (+3.86%) 05/04/23 Truist Enviva downgraded to Sell from Buy at Truist 04/06/23 RBC Capital Enviva price target lowered to $32 from $63 at RBC Capital 04/04/23 Truist Enviva price target lowered to $40 from $70 at Truist 04/04/23 Citi Enviva price target lowered to $32 from $62 at Citi ALGT Allegiant Travel $98.73 / -1.01 (-1.01%) 05/15/23 Raymond James Allegiant Travel price target raised to $123 from $118 at Raymond James 05/04/23 Susquehanna Allegiant Travel price target raised to $105 from $90 at Susquehanna 05/01/23 BofA Allegiant Travel downgraded to Underperform from Neutral at BofA 03/10/23 Barclays Allegiant Travel downgraded to Equal Weight from Overweight at Barclays APTV Aptiv $90.97 / -1.17 (-1.27%) 05/17/23 Guggenheim Aptiv price target lowered to $138 from $152 at Guggenheim 05/08/23 Barclays Aptiv price target lowered to $135 from $142 at Barclays 05/05/23 Deutsche Bank Aptiv price target lowered to $128 from $136 at Deutsche Bank 05/05/23 TD Cowen Aptiv price target lowered to $141 from $144 at TD Cowen BLNK Blink Charging $6.88 / -0.01 (-0.15%) 05/12/23 Barclays Blink Charging price target lowered to $10 from $11 at Barclays 05/11/23 DA Davidson Blink Charging price target lowered to $11 from $14 at DA Davidson 05/08/23 B. Riley Blink Charging price target lowered to $8 from $14 at B. Riley 04/25/23 Stifel Blink Charging price target lowered to $9 from $23 at Stifel DIOD Diodes $92.29 / -3.63 (-3.78%) 05/10/23 Wells Fargo Diodes price target lowered to $85 from $95 at Wells Fargo 02/08/23 Wells Fargo Diodes price target raised to $95 from $75 at Wells Fargo 02/07/23 Truist Diodes price target raised to $108 from $101 at Truist 02/07/23 TD Cowen Diodes price target raised to $110 from $95 at Cowen SWX MODG EVA DIOD BLNK APTV ALGT ACAD SWX Southwest Gas $58.69 / +0.385 (+0.66%) 05/09/23 Southwest Gas reports Q1 EPS $1.69, consensus $1.42 02/28/23 Southwest Gas reports Q4 adjusted EPS $1.16, consensus $1.58 MODG Topgolf Callaway $17.28 / +0.155 (+0.91%) 05/09/23 Topgolf Callaway sees Q2 revenue $1.17B-$1.195B, consensus $1.22B 05/09/23 Topgolf Callaway sees FY23 adjusted EPS 63c-69c, consensus 78c 05/09/23 Topgolf Callaway reports Q1 adjusted EPS 17c, consensus 16c 05/09/23 Topgolf Callaway reports Q1 EPS 13c, consensus 16c EVA Enviva $8.88 / +0.33 (+3.86%) 05/04/23 Enviva cuts 2023 adjusted EBITDA outlook to $200M-$250M from $305M-$355M 05/03/23 Enviva reports Q1 net loss ($116.8M) vs. ($45.3M) last year 03/01/23 Enviva sees FY23 adjusted EBITDA $305M-$335M 03/01/23 Enviva reports Q4 revenue $239.3M, consensus $422.3M DIOD Diodes $92.29 / -3.63 (-3.78%) 05/09/23 Diodes sees Q2 revenue $467M plus or minus 3%, consensus $480.55M 05/09/23 Diodes reports Q1 adjusted EPS $1.59, consensus $1.49 02/06/23 Diodes sees Q1 revenue $467M plus or minus 3%, consensus $466.93M 02/06/23 Diodes reports Q4 adjustedEPS $1.73, consensus $1.61 BLNK Blink Charging $6.88 / -0.01 (-0.15%) 05/09/23 Blink Charging sees FY23 revenue $100M-$110M, consensus $103.57M 05/09/23 Blink Charging reports Q1 EPS (53c), consensus (46c) 02/28/23 Blink Charging sees FY23 revenue $100M-$110M, consensus $91.57M 02/28/23 Blink Charging reports Q4 adjusted EPS (41c), consensus (48c) APTV Aptiv $90.97 / -1.17 (-1.27%) 05/04/23 Aptiv backs FY23 adjusted EPS view $4.00-$4.50, consensus $4.41 05/04/23 Aptiv reports Q1 adjusted EPS 91c, consensus 89c 02/02/23 Aptiv sees FY23 adjusted EPS $4.00-$4.50, consensus $4.73 02/02/23 Aptiv reports Q4 adjusted EPS $1.27, consensus $1.22 ALGT Allegiant Travel $98.73 / -1.01 (-1.01%) 05/16/23 Allegiant Travel reports April total system passengers down 0.1% y-o-y 05/03/23 Allegiant Travel reports Q1 EPS $3.04 ex items, consensus $2.30 02/01/23 Allegiant Travel sees FY23 airline EPS $9 02/01/23 Allegiant Travel reports Q4 adjusted EPS $3.17, consensus 69c ACAD Acadia Pharmaceuticals $23.73 / -1.055 (-4.26%) 05/08/23 Acadia Pharmaceuticals backs FY23 revenue view of $520M-$550M, consensus $556.5M 05/08/23 Acadia Pharmaceuticals reports Q1 EPS (27c), consensus (21c) 02/27/23 Acadia Pharmaceuticals sees FY23 revenue $520M-$550M, consensus $569.2M 02/27/23 Acadia Pharmaceuticals reports Q4 EPS (26c), consensus (24c) 08 Mar 07 Feb BLNK BLNK Blink Charging $6.88 / -0.01 (-0.15%) 02/10/23 DOT's coming EV charger rules may pressure Tesla to open network, Reuters says SWX MODG EVA BLNK APTV ALGT ACAD SWX Southwest Gas $58.69 / +0.385 (+0.66%) 03/23/23 Fly Intel: After-Hours Movers 03/20/23 Fly Insider: Southwest Gas, Pathward among week's notable insider trades 03/14/23 Fly Intel: After-Hours Movers MODG Topgolf Callaway $17.28 / +0.155 (+0.91%) 05/22/23 Fly Intel: After-Hours Movers 05/09/23 Fly Intel: After-Hours Movers 02/09/23 Fly Intel: After-Hours Movers EVA Enviva $8.88 / +0.33 (+3.86%) 05/05/23 Buy/Sell: Wall Street's top 10 stock calls this week 05/04/23 What You Missed On Wall Street On Thursday 05/04/23 What You Missed On Wall Street This Morning 01/20/23 Sell these stocks now, proven algorithm says BLNK Blink Charging $6.88 / -0.01 (-0.15%) 04/03/23 What You Missed This Week in EVs and Clean Energy 03/28/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/25/23 Short Report: Surprise GameStop profit spooks bears 03/06/23 What You Missed This Week in EVs and Clean Energy APTV Aptiv $90.97 / -1.17 (-1.27%) 02/22/23 Here's what Wall Street experts are saying about these EV names ahead of results 02/15/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations ALGT Allegiant Travel $98.73 / -1.01 (-1.01%) 05/01/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/06/23 Fly Insider Express, ServiceNow among week's notable insider trades 01/11/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations ACAD Acadia Pharmaceuticals $23.73 / -1.055 (-4.26%) 05/22/23 Biotech Alert: Searches spiking for these stocks today 00:00 Today 51st Annual Technology, Media & Telecom Conference 00:00 Today Diodes 06/01/23 ACADIA Pharmaceuticals Inc 06/06/23 Topgolf Callaway Brands Corp 06/15/23 Enviva Inc. 06/21/23 Allegiant Travel Company MODG BLNK APTV ACAD MODG Topgolf Callaway $17.28 / +0.155 (+0.91%) 05/24/23 Topgolf Callaway Brands call volume above normal and directionally bullish 02/09/23 Topgolf Callaway Brands options imply 5.8% move in share price post-earnings 12/20/22 Unusually active option classes on open December 20th BLNK Blink Charging $6.88 / -0.01 (-0.15%) 05/23/23 Largest borrow rate increases among liquid names 05/22/23 Blink Charging call volume above normal and directionally bullish 05/15/23 Largest borrow rate increases among liquid names 05/09/23 Blink Charging call volume above normal and directionally bullish APTV Aptiv $90.97 / -1.17 (-1.27%) 02/14/23 Early notable gainers among liquid option names on February 14th 01/27/23 Early notable gainers among liquid option names on January 27th ACAD Acadia Pharmaceuticals $23.73 / -1.055 (-4.26%) 04/11/23 Largest borrow rate increases among liquid names
Conference/Events	Oppenheimer biotech analyst to hold a reception » 15:23 05/30/23 05/30 15:23 05/30/23 15:23 AGEN Agenus $1.44 / -0.005 (-0.35%) , CGEN Compugen $1.05 / -0.02 (-1.87%) , DAWN Day One Biopharmaceuticals $12.04 / -0.435 (-3.49%) , ERAS Erasca $2.61 / -0.215 (-7.62%) , IMRX Immuneering $6.93 / +0.44 (+6.78%) , KNTE Kinnate Biopharma $3.69 / -0.05 (-1.34%) , MRTX Mirati Therapeutics $37.36 / -1.15 (-2.99%) , RVMD Revolution Medicines $24.84 / -0.8 (-3.12%) , VIRX Viracta Therapeutics $1.33 / -0.11 (-7.64%) , ONCT Oncternal Therapeutics / + , BMEA Biomea Fusion $33.75 / +2.21 (+7.01%) , MRNA Moderna $128.65 / +2.38 (+1.88%) , REGN Regeneron $723.84 / -1.76 (-0.24%) , AZN AstraZeneca $71.39 / -1.12 (-1.54%) , GILD Gilead $76.36 / -0.72 (-0.93%) , VSTM Verastem $1.04 / +0.015 (+1.47%) , SWTX SpringsWorks Therapeutics $27.54 / -0.25 (-0.90%) Biotech Analysts… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 15:23 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options VSTM VIRX SWTX RVMD REGN ONCT MRTX MRNA KNTE IMRX GILD ERAS DAWN CGEN BMEA AZN AGEN VSTM Verastem $1.04 / +0.015 (+1.47%) 05/25/23 Verastem's vutometinib shows 45% response rate in recurrent ovarian cancer 04/26/23 Interim analysis of Verastem's RAMP 201 trial to be presented at ASCO 01/24/23 Verastem reports interim data from Part A of the ongoing RAMP 201 Phase 2 study VIRX Viracta Therapeutics $1.33 / -0.11 (-7.64%) 05/02/23 Viracta Therapeutics CMO Lisa Rojkjaer, M.D to depart 01/19/23 Viracta Therapeutics announces EC orphan drug designation for Nana-val 01/08/23 Viracta announces first clinical response in EBV+ solid tumor setting 11/30/22 Viracta reports Phase 1b/2 trial results for Nana-val in EBV+ tumors SWTX SpringsWorks Therapeutics $27.54 / -0.25 (-0.90%) 05/30/23 SpringsWorks Therapeutics says Phase 2 nirogacestat trial fully enrolled 04/17/23 MapKure, SpringWorks, BeiGene present data from Phase 1a/1b study of BGB-3245 02/27/23 SpringsWorks announces FDA acceptance, priority review of nirogacestat NDA 12/27/22 SpringsWorks Therapeutics completes submission of nirogacestat NDA to FDA RVMD Revolution Medicines $24.84 / -0.8 (-3.12%) 12/19/22 Revolution Medicines announces publication on design, synthesis of RMC-5552 12/07/22 Revolution to regain rights to RMC-4630 following Sanofi deal termination 12/07/22 Sanofi terminates SHP2 Inhibitor development pact with Revolution Medicines REGN Regeneron $723.84 / -1.76 (-0.24%) 05/25/23 Regeneron says updated Linvoseltamab data demonstrates durable responses 05/25/23 Regeneron reports 'positive' data from Fianlimab-Libtayo combo trial 05/21/23 Regeneron, Sanofi present Dupixent late-breaking Phase 3 COPD results 05/18/23 Sanofi 'pleased' with Supreme Court's ruling on Amgen's asserted patent claims ONCT Oncternal Therapeutics / + 04/03/23 Oncternal Therapeutics falls 41% to 46c per share after drug development halt 04/03/23 Oncternal Therapeutics trading resumes 04/03/23 Oncternal Therapeutics to resume trading at 4:30pm ET 04/03/23 Oncternal Therapeutics halts development of zilovertamab, ibrutinib combination MRTX Mirati Therapeutics $37.36 / -1.15 (-2.99%) 05/24/23 Mirati Therapeutics falls 10% after SAPPHIRE study did not meet primary endpoint 05/24/23 Mirati Therapeutics trading resumes 05/24/23 Mirati Therapeutics says SAPPHIRE study did not meet primary endpoint 05/24/23 Mirati Therapeutics trading halted, news pending MRNA Moderna $128.65 / +2.38 (+1.88%) 05/23/23 Moderna, BioNTech other Covid vaccine makers jump amid China Covid scare 05/19/23 Moderna reports interim data from Phase 1/2 trial of mRNA-3927 05/04/23 Moderna up 5% after Q1 results beat estimates 05/04/23 Moderna, Novocol Pharma enter long-term fill-finish agreement KNTE Kinnate Biopharma $3.69 / -0.05 (-1.34%) 04/17/23 Kinnate Biopharma adds two candidates to pipeline, provides cash runway guidance 04/17/23 Kinnate Biopharma announces 'positive' monotherapy dose escalation data 02/21/23 Kinnate Biopharma acquires ownership stake of Kinnjiu Biopharma for $24M 02/14/23 Kinnate Biopharma granted fast track designation for KIN-3248 from FDA IMRX Immuneering $6.93 / +0.44 (+6.78%) 04/18/23 Immuneering down 5% at $11.53 after pricing $30M stock offering 04/18/23 Immuneering announces initial Phase 1 PK, PD, safety data for IMM-1-104 03/28/23 Immuneering appoints Harold Brakewood as CBO 03/05/23 Immuneering presents preclinical data with lead program IMM-1-104 GILD Gilead $76.36 / -0.72 (-0.93%) 05/26/23 Gilead announces CHMP reccomendation for the use of Veklury 05/17/23 Gilead to present advances across its oncology pipeline at ASCO Annual Meeting 05/15/23 Arcus Biosciences jumps 2% amid expanded inflammation pact with Gilead 05/15/23 Expanded Gilead- Arcus pact may result in up to $1B in payments to Arcus ERAS Erasca $2.61 / -0.215 (-7.62%) 05/25/23 Erasca to present HERKULES-3 phase 1b data for ERAS-007 at ASCO 05/16/23 Erasca appoints Davd Chacko as CBO, Nik Chetwyn as COO 05/01/23 Erasca announces U.S. FDA granted FTD to ERAS-801 04/25/23 Erasca announces publication of clinical data on naporafenib DAWN Day One Biopharmaceuticals $12.04 / -0.435 (-3.49%) 01/08/23 Day One announces top line data from pivotal Phase 2 FIREFLY-1 trial CGEN Compugen $1.05 / -0.02 (-1.87%) 03/06/23 Compugen doses first patient in proof-of-concept study evaluating COM701 02/14/23 Compugen: Rilvegostomig expected to progress into Phase 3 this year 12/06/22 Compugen's COM701 shows durable anti-tumor activity in ovarian cancer 12/01/22 Compugen's COM701 shows preliminary anti-tumor activity in ovarian cancer BMEA Biomea Fusion $33.75 / +2.21 (+7.01%) 05/01/23 Biomea says FDA clearance of IND application to begin Phase I trial of BMF-500 04/19/23 Biomea Fusion to present late breaking data from Phase II trial, COVALENT-111 03/28/23 Biomea Fusion trading resumes 03/28/23 Biomea Fusion trading halted, volatility trading pause AZN AstraZeneca $71.39 / -1.12 (-1.54%) 05/30/23 BioLight announces joint cooperation agreement with AstraZeneca's Alexion 05/30/23 Catalyst Pharmaceuticals appoints Thompson to board of directors 05/30/23 Bolt Biotherapeutics and AstraZeneca Rare Disease partner in retinal disease R&D 05/26/23 AstraZeneca announces results from Imfinzi plus Lynparza trial AGEN Agenus $1.44 / -0.005 (-0.35%) 05/03/23 Agenus up 4% after FDA approves GSK's Arexvy RSV vaccine 04/26/23 Agenus to present Phase 1, Phase 2 trial data at ASCO meeting 04/17/23 Agenus receives Fast Track Designation from FDA for botensilimab, balstilimab 03/27/23 Agenus announces results from cohort in study of botensilimab with balstilimab AGEN CGEN DAWN ERAS IMRX KNTE MRTX RVMD VIRX ONCT BMEA MRNA REGN AZN GILD VSTM SWTX AGEN Agenus $1.44 / -0.005 (-0.35%) 05/25/23 EF Hutton Agenus assumed with a Buy at EF Hutton 05/09/23 H.C. Wainwright Agenus's progress continues with data presentations, says H.C. Wainwright 04/20/23 B. Riley B. Riley came away 'encouraged' on Agenus after AACR 02/28/23 H.C. Wainwright Agenus assumed with a Buy at H.C. Wainwright CGEN Compugen $1.05 / -0.02 (-1.87%) 02/08/23 Jefferies Compugen downgraded to Underperform from Hold at Jefferies 01/04/23 EF Hutton Compugen initiated with a Buy at EF Hutton 11/14/22 Oppenheimer Compugen price target lowered to $8 from $12 at Oppenheimer 08/23/22 Truist Compugen price target lowered to $4 from $14 at Truist DAWN Day One Biopharmaceuticals $12.04 / -0.435 (-3.49%) 05/01/23 Oppenheimer Day One language around NDA submission 'sounded ominous,' says Oppenheimer 05/01/23 H.C. Wainwright Day One pullback brings attractive entry point, says H.C. Wainwright 04/25/23 BofA Day One Biopharmaceuticals double downgraded at BofA on regulatory risks 04/25/23 BofA Day One Biopharmaceuticals downgraded to Underperform from Buy at BofA ERAS Erasca $2.61 / -0.215 (-7.62%) 03/29/23 Mizuho Erasca initiated with a Buy at Mizuho 02/24/23 Goldman Sachs Erasca initiated with a Buy at Goldman Sachs 02/03/23 Morgan Stanley Erasca upgraded to Overweight from Equal Weight at Morgan Stanley IMRX Immuneering $6.93 / +0.44 (+6.78%) 04/19/23 Mizuho Immuneering upgraded to Buy from Neutral at Mizuho 04/19/23 Morgan Stanley Immuneering upgraded to Equal Weight from Underweight at Morgan Stanley 04/18/23 Chardan Immuneering price target raised to $22 from $18 at Chardan 03/29/23 Mizuho Immuneering initiated with a Neutral at Mizuho KNTE Kinnate Biopharma $3.69 / -0.05 (-1.34%) 05/18/23 H.C. Wainwright Kinnate Biopharma price target lowered to $24 from $25 at H.C. Wainwright 04/20/23 H.C. Wainwright Kinnate Biopharma price target lowered to $25 from $33 at H.C. Wainwright 04/18/23 Stifel Kinnate Biopharma price target lowered to $5 from $8 at Stifel 04/18/23 Wedbush Kinnate Biopharma price target lowered to $14 from $25 at Wedbush MRTX Mirati Therapeutics $37.36 / -1.15 (-2.99%) 05/25/23 Oppenheimer Oppenheimer upgrades Mirati to Outperform with Krazati expectations reset 05/25/23 Oppenheimer Mirati Therapeutics upgraded to Outperform from Perform at Oppenheimer 05/25/23 BMO Capital Mirati Therapeutics price target lowered to $40 from $50 at BMO Capital 05/25/23 Barclays Mirati Therapeutics price target lowered to $75 from $90 at Barclays RVMD Revolution Medicines $24.84 / -0.8 (-3.12%) 05/09/23 JPMorgan Revolution Medicines price target lowered to $35 from $38 at JPMorgan 02/28/23 Needham Revolution Medicines price target raised to $38 from $32 at Needham 02/28/23 Oppenheimer Revolution Medicines price target raised to $35 from $30 at Oppenheimer 02/28/23 JPMorgan Revolution Medicines upgraded to Overweight from Neutral at JPMorgan VIRX Viracta Therapeutics $1.33 / -0.11 (-7.64%) 05/10/23 H.C. Wainwright Viracta Therapeutics price target lowered to $33 from $35 at H.C. Wainwright ONCT Oncternal Therapeutics / + 04/06/23 Cantor Fitzgerald Oncternal downgraded to Neutral from Overweight at Cantor Fitzgerald 04/04/23 Maxim Oncternal Therapeutics downgraded to Hold from Buy at Maxim 04/04/23 Cantor Fitzgerald Oncternal Therapeutics price target lowered to $1.30 from $4.00 at Cantor Fitzgerald 04/04/23 H.C. Wainwright Oncternal Therapeutics downgraded to Neutral from Buy at H.C. Wainwright BMEA Biomea Fusion $33.75 / +2.21 (+7.01%) 05/25/23 EF Hutton Biomea Fusion assumed with a Buy at EF Hutton 05/18/23 Citi Biomea Fusion price target lowered to $53 from $55 at Citi 05/12/23 Barclays Biomea Fusion initiated with an Overweight at Barclays 04/19/23 H.C. Wainwright Biomea Fusion price target lowered to $37 from $44 at H.C. Wainwright MRNA Moderna $128.65 / +2.38 (+1.88%) 05/05/23 Morgan Stanley Moderna price target lowered to $153 from $185 at Morgan Stanley 04/25/23 Guggenheim Moderna initiated with a Neutral at Guggenheim 04/13/23 Baird Carisma Therapeutics initiated with an Outperform at Baird 04/12/23 BofA BofA says 'left with more questions than answers' after Moderna Vaccines Day REGN Regeneron $723.84 / -1.76 (-0.24%) 05/19/23 Piper Sandler Regeneron Q1 Eylea miss 'not about share, says Piper Sandler 05/08/23 Guggenheim Regeneron price target lowered to $935 from $960 at Guggenheim 05/05/23 Morgan Stanley Regeneron price target raised to $927 from $880 at Morgan Stanley 05/05/23 SVB Securities Regeneron price target lowered to $895 from $976 at SVB Securities AZN AstraZeneca $71.39 / -1.12 (-1.54%) 05/26/23 Argus AstraZeneca price target lowered to $80 from $85 at Argus 05/09/23 Berenberg AstraZeneca price target raised to 135 GBp from 124 GBp at Berenberg 04/28/23 JPMorgan AstraZeneca price target raised to 14,000 GBp from 13,500 GBp at JPMorgan 04/13/23 Argus AstraZeneca price target raised to $85 from $75 at Argus GILD Gilead $76.36 / -0.72 (-0.93%) 05/16/23 BMO Capital Gilead upgraded to Outperform from Market Perform at BMO Capital 04/28/23 Piper Sandler Gilead assumed with an Overweight at Piper Sandler 04/12/23 Morgan Stanley Gilead price target raised to $85 from $81 at Morgan Stanley 04/05/23 Guggenheim InflaRx upgraded to Buy at Guggenheim after Gohibic gets COVID EUA VSTM Verastem $1.04 / +0.015 (+1.47%) 05/10/23 H.C. Wainwright Verastem price target lowered to $2 from $3 at H.C. Wainwright 03/29/23 Mizuho Verastem initiated with a Neutral at Mizuho 11/07/22 H.C. Wainwright Verastem price target lowered to $3 from $5 at H.C. Wainwright 10/05/22 BTIG Verastem price target lowered to $5 from $8 at BTIG SWTX SpringsWorks Therapeutics $27.54 / -0.25 (-0.90%) 04/28/23 Barclays SpringsWorks Therapeutics price target lowered to $41 from $55 at Barclays 03/07/23 H.C. Wainwright SpringsWorks Therapeutics price target raised to $105 from $99 at H.C. Wainwright 01/02/23 Barclays Barclays views GSK acquisition interest as positive for oncology stocks 12/01/22 BofA SpringsWorks Therapeutics initiated with a Buy, $45 price target at BofA VSTM VIRX SWTX RVMD REGN ONCT MRTX MRNA KNTE GILD ERAS DAWN CGEN BMEA AZN AGEN VSTM Verastem $1.04 / +0.015 (+1.47%) 05/09/23 Verastem reports Q1 EPS (9c), consensus (8c) 03/14/23 Verastem reports Q4 EPS (8c), consensus (10c) VIRX Viracta Therapeutics $1.33 / -0.11 (-7.64%) 05/08/23 Viracta Therapeutics reports Q1 EPS (32c), consensus (31c) 03/13/23 Viracta Therapeutics reports Q4 EPS (27c), consensus (38c) SWTX SpringsWorks Therapeutics $27.54 / -0.25 (-0.90%) 05/03/23 SpringsWorks Therapeutics reports Q1 EPS ($1.18), consensus ($1.25) 02/28/23 SpringsWorks Therapeutics reports Q4 EPS ($1.19), consensus ($1.22) RVMD Revolution Medicines $24.84 / -0.8 (-3.12%) 05/08/23 Revolution Medicines reports Q1 EPS (72c), consensus (81c) 02/27/23 Revolution Medicines sees FY23 net loss $335M-$365M 02/27/23 Revolution Medicines reports Q4 EPS (63c), consensus (82c) REGN Regeneron $723.84 / -1.76 (-0.24%) 05/04/23 Regeneron reports Q1 adjusted EPS $10.09, consensus $9.56 02/03/23 Regeneron reports Q4 adjusted EPS $12.56, consensus $10.03 02/02/23 Notable companies reporting before tomorrow's open ONCT Oncternal Therapeutics / + 05/04/23 Oncternal Therapeutics reports Q1 EPS (20c), consensus (20c) MRTX Mirati Therapeutics $37.36 / -1.15 (-2.99%) 05/09/23 Mirati Therapeutics reports Q1 EPS ($3.18), consensus ($3.55) 02/28/23 Mirati Therapeutics reports Q4 EPS ($3.51), consensus ($3.55) MRNA Moderna $128.65 / +2.38 (+1.88%) 05/04/23 Moderna sees Q2 sales $200M-$300M, consensus $982.37M 02/23/23 Moderna reports Q4 EPS $3.61, consensus $4.67 02/22/23 Notable companies reporting before tomorrow's open KNTE Kinnate Biopharma $3.69 / -0.05 (-1.34%) 05/11/23 Kinnate Biopharma reports Q1 EPS (73c), consensus (73c) GILD Gilead $76.36 / -0.72 (-0.93%) 05/15/23 Gilead: Arcus deal may reduce Gilead's FY23 GAAP and non-GAAP EPS by 2c 04/27/23 Gilead backs FY23 adjusted EPS view $6.60-$7.00, consensus $6.84 04/27/23 Gilead reports Q1 Biktarvy sales up 24% y/y 04/27/23 Gilead Sciences reports Q1 adjusted EPS $1.37, consensus $1.54 ERAS Erasca $2.61 / -0.215 (-7.62%) 05/15/23 Erasca reports Q1 EPS (22c), consensus (31c) 03/23/23 Erasca reports Q4 EPS ($1.06) vs. (26c) last year DAWN Day One Biopharmaceuticals $12.04 / -0.435 (-3.49%) 05/01/23 Day One Biopharmaceuticals reports Q1 EPS (59c), consensus (59c) CGEN Compugen $1.05 / -0.02 (-1.87%) 05/15/23 Compugen reports Q1 EPS (11c), consensus (12c) 03/10/23 Compugen considers exposure to SVB Financial as immaterial 02/27/23 Compugen reports Q4 EPS (4c), consensus (14c) BMEA Biomea Fusion $33.75 / +2.21 (+7.01%) 05/02/23 Biomea Fusion reports Q1 EPS (98c), consensus (81c) 03/28/23 Biomea Fusion reports Q4 EPS (21c), consensus (81c) AZN AstraZeneca $71.39 / -1.12 (-1.54%) 04/27/23 AstraZeneca sees FY23 core EPS up high single to low double-digit percentage 04/27/23 AstraZeneca reports Q1 core EPS $1.92, consensus $1.07 02/09/23 AstraZeneca sees FY23 core EPS up high single to low double-digit percentage 02/09/23 AstraZeneca reports Q4 core EPS $1.38, consensus $1.35 AGEN Agenus $1.44 / -0.005 (-0.35%) 05/09/23 Agenus reports Q1 EPS (22c), consensus (21c) 03/14/23 Agenus reports Q4 EPS (24c), consensus (22c) 18 Apr 30 Mar 03 Mar 09 Dec 20 Jul 15 Jun REGN MRTX MRNA AZN REGN Regeneron $723.84 / -1.76 (-0.24%) 05/17/23 Regeneron CEO backs regulators attempt to block Amgen deal, FT reports MRTX Mirati Therapeutics $37.36 / -1.15 (-2.99%) 05/09/23 Boxer's Davis pitches Mirati Therapeutics as long idea at Sohn MRNA Moderna $128.65 / +2.38 (+1.88%) 05/26/23 Health authorities to target next COVID shot to new strain, WSJ says 05/23/23 China's new Covid surge could result in 65M infections a week, Bloomberg says 03/23/23 Moderna CEO defends $130 price of Covid-19 vaccine, Reuters reports 03/21/23 FDA moving towards authorizing second omicron booster, WSJ reports AZN AstraZeneca $71.39 / -1.12 (-1.54%) 05/19/23 Astra China head says company seeks to 'love the Communist Party,' Reuters says 05/04/23 AstraZeneca chair says increasing CEO's pay wards of rivals, FT reports 04/06/23 GSK unit ordered to pay AstraZeneca royalties on Zejula sales, Reuters says VSTM SWTX RVMD REGN ONCT MRTX MRNA KNTE GILD ERAS DAWN BMEA AZN AGEN VSTM Verastem $1.04 / +0.015 (+1.47%) 03/14/23 Fly Intel: After-Hours Movers SWTX SpringsWorks Therapeutics $27.54 / -0.25 (-0.90%) 04/22/23 Short Report: Bears pare exposure in crypto stocks as bitcoin slumps RVMD Revolution Medicines $24.84 / -0.8 (-3.12%) 02/28/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations REGN Regeneron $723.84 / -1.76 (-0.24%) 03/28/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/27/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/24/23 What You Missed On Wall Street On Friday 03/24/23 What You Missed On Wall Street This Morning ONCT Oncternal Therapeutics / + 04/06/23 Biotech Alert: Searches spiking for these stocks today 04/04/23 Fly Intel: Pre-market Movers 04/03/23 Fly Intel: After-Hours Movers 12/07/22 Biotech Alert: Searches spiking for these stocks today MRTX Mirati Therapeutics $37.36 / -1.15 (-2.99%) 05/25/23 Fly Intel: Pre-market Movers 02/19/23 Short Report: Bearish bets in crypto arena renewed as coins and stocks rebound 12/31/22 Short Report: Bearish views reach record high on Silvergate, Mirati Therapeutics 12/16/22 Sell these stocks now, proven algorithm says MRNA Moderna $128.65 / +2.38 (+1.88%) 04/26/23 What You Missed On Wall Street On Wednesday 04/26/23 What You Missed On Wall Street This Morning 04/14/23 Biotech Alert: Searches spiking for these stocks today 04/13/23 Biotech Alert: Searches spiking for these stocks today KNTE Kinnate Biopharma $3.69 / -0.05 (-1.34%) 05/15/23 Fly Insider: Kinnate Biopharma, Arrowhead among week's notable insider trades GILD Gilead $76.36 / -0.72 (-0.93%) 05/16/23 What You Missed On Wall Street On Tuesday 05/16/23 What You Missed On Wall Street This Morning 05/16/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/28/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations ERAS Erasca $2.61 / -0.215 (-7.62%) 03/23/23 Fly Intel: After-Hours Movers 02/24/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/09/22 What You Missed On Wall Street On Friday 12/09/22 What You Missed On Wall Street This Morning DAWN Day One Biopharmaceuticals $12.04 / -0.435 (-3.49%) 04/28/23 Buy/Sell: Wall Street's top 10 stock calls this week 04/25/23 What You Missed On Wall Street On Tuesday 04/25/23 What You Missed On Wall Street This Morning 04/25/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations BMEA Biomea Fusion $33.75 / +2.21 (+7.01%) 04/10/23 Fly Insider: Planet Labs, C3.ai among week's notable insider trades 03/28/23 What You Missed On Wall Street On Tuesday 03/28/23 What You Missed On Wall Street This Morning AZN AstraZeneca $71.39 / -1.12 (-1.54%) 04/11/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/05/23 What You Missed On Wall Street On Wednesday 04/05/23 What You Missed On Wall Street This Morning 02/09/23 What You Missed On Wall Street This Morning AGEN Agenus $1.44 / -0.005 (-0.35%) 04/17/23 What You Missed On Wall Street On Monday 04/17/23 What You Missed On Wall Street This Morning 01/23/23 What You Missed On Wall Street On Monday 01/23/23 What You Missed On Wall Street This Morning 06/02/23 Biotechnology--Pre-ASCO Reception 06/09/23 Biotechnology 06/12/23 Biotech/Biopharma 05/30/23 4th Annual Oncology Innovation Summit: Insights for ASCO & EHA 06/02/23 2023 ASCO Annual Meeting 09/19/23 Institutional Investor Conference 2023 11:00 Today Verastem - VSTM 06/27/23 PDUFA Date for Eylea 08/20/23 PDUFA Date for Pozelimab 08/27/23 PDUFA Date for Nirogacestat 12/22/23 PDUFA Date for Eplontersen 06/08/23 Revolution Medicines, Inc. 06/08/23 Viracta Therapeutics Inc 06/09/23 Regeneron Pharmaceuticals 06/09/23 Kinnate Biopharma Inc. 06/12/23 Agenus Inc. 06/13/23 Compugen 06/14/23 Compugen 06/14/23 Immuneering Corp. 06/14/23 BioMea Fusion, Inc. 06/15/23 Compugen 06/22/23 Day One Biopharmaceuticals, Inc 06/22/23 Erasca, Inc. 06/28/23 Oncternal Therapeutics Inc REGN MRNA GILD BMEA AZN REGN Regeneron $723.84 / -1.76 (-0.24%) 03/23/23 Early notable gainers among liquid option names on March 23rd MRNA Moderna $128.65 / +2.38 (+1.88%) 05/24/23 Unusually active option classes on open May 24th 05/23/23 Moderna call volume above normal and directionally bullish 05/23/23 Early notable gainers among liquid option names on May 23rd 04/17/23 Unusually active option classes on open April 17th GILD Gilead $76.36 / -0.72 (-0.93%) 05/25/23 Gilead call volume above normal and directionally bullish 05/03/23 Gilead call volume above normal and directionally bullish 04/27/23 Gilead options imply 3.8% move in share price post-earnings 02/03/23 Early notable gainers among liquid option names on February 3rd BMEA Biomea Fusion $33.75 / +2.21 (+7.01%) 03/28/23 Biomea Fusion options imply 11.3% move in share price post-earnings AZN AstraZeneca $71.39 / -1.12 (-1.54%) 05/26/23 Unusually active option classes on open May 26th 05/18/23 Unusually active option classes on open May 18th 05/09/23 AstraZeneca put volume heavy and directionally bearish 04/27/23 Unusually active option classes on open April 27th

Thursday
Hot Stocks	Erasca to present HERKULES-3 phase 1b data for ERAS-007 at ASCO » 17:02 05/25/23 05/25 17:02 05/25/23 17:02 ERAS Erasca $2.97 / -0.04 (-1.33%) Erasca announced… Erasca announced preliminary Phase 1b data for ERAS-007 combinations in patients with GI malignancies from two poster presentations at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois. The posters will be available online at Erasca.com/science/presentations. "Early clinical data from HERKULES-3 continue to reinforce the potential to combine ERAS-007 with multiple agents and its potential as a backbone therapy to treat patients with GI malignancies. Importantly, these preliminary findings support a data-driven approach to refine the focus of our initial clinical development efforts on indications holding significant promise," said Jonathan E. Lim, M.D., Erasca's chairman, CEO, and co-founder. "Our initial evaluation of the ERAS-007 + EC combination in patients with BRAF-mutated metastatic CRC will focus on EC-naive patients based on the preliminary activity observed in HERKULES-3. By evaluating efficacy and safety in a larger sample size of patients treated at the 100 mg BID-QW dose of ERAS-007 with EC, we believe we will be able to better assess whether the promising response rate and duration of treatment observed with the triplet can be maintained." ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events ERAS Erasca $2.97 / -0.04 (-1.33%) 05/16/23 Erasca appoints Davd Chacko as CBO, Nik Chetwyn as COO 05/01/23 Erasca announces U.S. FDA granted FTD to ERAS-801 04/25/23 Erasca announces publication of clinical data on naporafenib 04/18/23 Erasca presents Phase 1b dose escalation data from FLAGSHIP-1 for ERAS-601 ERAS Erasca $2.97 / -0.04 (-1.33%) 03/29/23 Mizuho Erasca initiated with a Buy at Mizuho 02/24/23 Goldman Sachs Erasca initiated with a Buy at Goldman Sachs 02/03/23 Morgan Stanley Erasca upgraded to Overweight from Equal Weight at Morgan Stanley ERAS Erasca $2.97 / -0.04 (-1.33%) 05/15/23 Erasca reports Q1 EPS (22c), consensus (31c) 03/23/23 Erasca reports Q4 EPS ($1.06) vs. (26c) last year 09 Dec ERAS Erasca $2.97 / -0.04 (-1.33%) 03/23/23 Fly Intel: After-Hours Movers 02/24/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/09/22 What You Missed On Wall Street On Friday 12/09/22 What You Missed On Wall Street This Morning 06/02/23 Biotechnology--Pre-ASCO Reception 06/22/23 Erasca, Inc.
On The Fly	Rising High: Exclusive talk with financial services firm Safe Harbor » 11:34 05/25/23 05/25 11:34 05/25/23 11:34 RLMD Relmada Therapeutics $2.83 / -0.27 (-8.71%) , CMPS Compass Pathways $7.60 / -0.29 (-3.68%) , ATAI Atai Life Sciences $1.80 / -0.02 (-1.10%) , ZYNE Zynerba / + , TCNNF Trulieve Cannabis $4.45 / -0.01 (-0.22%) , CANN Trees Corporation / + , TLRY Tilray $2.37 / -0.045 (-1.87%) , IGC India Globalization Capital / + , GTBIF Green Thumb Industries $7.48 / +0.07 (+0.94%) , GDNSF Goodness Growth / + , CRON Cronos Group $1.82 / -0.065 (-3.45%) , CGC Canopy Growth $1.01 / -0.04 (-3.83%) , CVSI CV Sciences / + , ACB Aurora Cannabis / + , FISI Financial Institutions $16.43 / -0.18 (-1.08%) , SHFS SHF Holdings / + In this edition of… Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options ZYNE TLRY TCNNF SHFS RLMD IGC GTBIF GDNSF FISI CVSI CRON CMPS CGC CANN ATAI ACB ZYNE Zynerba / + 05/15/23 Zynerba expects cash to fund operations to mid-year 2024 04/27/23 Bipartisan lawmakers reintroduce Safe Banking Act for cannabis businesses 04/12/23 Zynerba presents data on Zygel at 55th Gatlinburg Conference 03/13/23 Zynerba confirms does not hold cash deposits, securities at Silicon Valley Bank TLRY Tilray $2.37 / -0.045 (-1.87%) 05/25/23 Tilray's SweetWater Brewing announces summer release of American Lager 05/25/23 Tilray announces European market expansion in Italy 05/18/23 SweetWater Brewing introduces Colorado Orange Citrus Ale 05/18/23 Tilray's Breckenridge announces limited edition collaboration with Flaviar TCNNF Trulieve Cannabis $4.45 / -0.01 (-0.22%) 01/13/23 Trulieve CAO Rebecca Young departs 12/02/22 White House announces signing of medical marijuana research expansion act SHFS SHF Holdings / + 05/23/23 Safe Harbor's Social Equity Program opens 13 new accounts 05/16/23 SHF Holdings originates real estate loans for tier-one multi-state operator 04/17/23 Safe Harbor resolves $68.6M in debt obligations RLMD Relmada Therapeutics $2.83 / -0.27 (-8.71%) 01/09/23 Relmada Therapeutics names Cedric O'Gorman MD as Chief Medical Officer 12/07/22 Relmada Therapeutics trading resumes 12/07/22 Relmada Therapeutics' REL-1017 in depressive disorder did not reach endpoint 12/07/22 Relmada Therapeutics trading halted, news pending IGC India Globalization Capital / + 03/20/23 India Globalization Capital announces rebranding to IGC Pharma 01/04/23 India Globalization Capital receives no objection letter from Health Canada 12/20/22 India Globalization Capital announces updated life sciences presentation GTBIF Green Thumb Industries $7.48 / +0.07 (+0.94%) 05/23/23 Green Thumb Industries to open RISE Bristol, new retail location 04/27/23 Green Thumb Industries appoints Ethan Nadelmann to board of directors 04/25/23 Green Thumb Industries announces official Dead & Copany after-party GDNSF Goodness Growth / + 05/25/23 Goodness Growth, Grown Rogue announce strategic advisory agreement 05/01/23 Goodness Growth closes on initial $2M tranche of $10M financing commitment 02/14/23 Goodness Growth appoints Josh Rosen as interim CEO, reorganizes management FISI Financial Institutions $16.43 / -0.18 (-1.08%) 05/11/23 SHF Holdings partners with Five Star Bank to expand access to cannabis banking 02/17/23 Financial Institutions increases quarterly dividend 3.4% CVSI CV Sciences / + 03/23/23 CV Sciences reports formal notice of patent issuance from JPO CRON Cronos Group $1.82 / -0.065 (-3.45%) 04/21/23 Cronos Group releases cannabinoid life cycle study on sustainable fermentation 02/08/23 Cronos says Spinach is top-selling edible brand in Canada in January 12/19/22 Cronos Group receives notice of relinquishment of warrant by Altria Group CMPS Compass Pathways $7.60 / -0.29 (-3.68%) 05/18/23 Enveric jumps over 100% after USPTO gives NOA for psilocin drug to treat anxiety 05/02/23 Compass, MAPS PBC announce AMA has approved code for psychedelic therapies 02/28/23 Compass Pathways sees 2023 net cash use $85M-$110M 01/26/23 Cathie Wood's ARK Investment bought 120.3K shares of Compass Pathways today CGC Canopy Growth $1.01 / -0.04 (-3.83%) 05/22/23 Canopy Growth files proxy statement, modifies structure, for listing compliance 05/09/23 Acreage Holdings CFO Steve Goertz resigns 03/21/23 Acreage obtains final order for strategic arrangement with Canopy Growth CANN Trees Corporation / + 12/20/22 Trees Corporation closes Green Man acquisition 12/13/22 Trees Corporation closes Green Tree acquisition ATAI Atai Life Sciences $1.80 / -0.02 (-1.10%) 04/17/23 Curaleaf spikes over 7% after NJ CRC Board reverses, okays adult use renewals 04/13/23 Atai Life Sciences doses first subject in Phase 1 study of PCN-101 in depression 03/30/23 Atai Life Sciences CEO Brand buys 70K shares of company stock ACB Aurora Cannabis / + 04/26/23 Aurora Cannabis partners with Strainprint for tracking program 03/24/23 Aurora Cannabis announces Nasdaq notice of non-compliance RLMD CMPS ATAI ZYNE TCNNF CANN TLRY IGC GTBIF GDNSF CRON CGC CVSI ACB FISI SHFS RLMD Relmada Therapeutics $2.83 / -0.27 (-8.71%) 12/08/22 Truist Relmada Therapeutics price target lowered to $4 from $7 at Truist 11/11/22 SVB Securities Relmada 'still has a chance' for positive depression data, says SVB 10/14/22 BofA Axsome shares could react positively to Relmada trial failure, says BofA 10/14/22 Goldman Sachs Relmada Therapeutics downgraded to Neutral from Buy at Goldman Sachs CMPS Compass Pathways $7.60 / -0.29 (-3.68%) 01/09/23 Loop Capital Atai Life Sciences price target lowered to $10 from $18 at Loop Capital 12/15/22 EF Hutton Compass Pathways initiated with a Buy at EF Hutton 12/09/22 Oppenheimer Compass Pathways price target lowered to $33 from $55 at Oppenheimer 11/01/22 Loop Capital Compass Pathways initiated with a Buy at Loop Capital ATAI Atai Life Sciences $1.80 / -0.02 (-1.10%) 01/19/23 H.C. Wainwright Atai Life Sciences price target lowered to $20 from $50 at H.C. Wainwright 01/09/23 Canaccord Atai Life Sciences price target lowered to $11 from $27 at Canaccord 01/09/23 Citi Atai Life Sciences price target lowered to $10 from $20 at Citi ZYNE Zynerba / + 05/16/23 Canaccord Zynerba price target lowered to $10 from $11 at Canaccord 11/09/22 Bernstein Two more states legalize cannabis, $3B added to TAM, says Bernstein 06/23/22 Canaccord Zynerba price target raised to $11 from $9 at Canaccord TCNNF Trulieve Cannabis $4.45 / -0.01 (-0.22%) 05/11/23 Stifel Trulieve Cannabis price target lowered to C$20 from C$25 at Stifel 05/11/23 Canaccord Trulieve Cannabis price target lowered to C$33 from C$40 at Canaccord 05/11/23 Alliance Global Partners Trulieve Cannabis price target lowered to C$16 from C$24 at Alliance Global Partners 03/09/23 Stifel Trulieve Cannabis price target lowered to C$25 from C$34 at Stifel CANN Trees Corporation / + TLRY Tilray $2.37 / -0.045 (-1.87%) 04/12/23 Roth MKM Tilray price target lowered to $2.50 from $3.00 at Roth MKM 04/11/23 TD Cowen Tilray price target lowered to $5 from $9 at TD Cowen 01/10/23 MKM Partners Tilray price target lowered to $3 from $4 at MKM Partners 01/10/23 Canaccord Tilray price target lowered to $5 from $7 at Canaccord IGC India Globalization Capital / + GTBIF Green Thumb Industries $7.48 / +0.07 (+0.94%) 05/04/23 Canaccord Green Thumb Industries price target lowered to C$24 from C$26 at Canaccord 03/03/23 Wedbush Green Thumb Industries price target lowered to $12 from $18 at Wedbush 03/01/23 Canaccord Green Thumb Industries price target lowered to C$26 from C$27 at Canaccord 03/01/23 Alliance Global Partners Green Thumb price target lowered to C$21 from C$24 at Alliance Global GDNSF Goodness Growth / + 11/16/22 Canaccord Goodness Growth price target lowered to C$0.85 from C$1 at Canaccord 10/14/22 Alliance Global Partners Verano Holdings price target lowered to C$12 from C$16 at Alliance Global CRON Cronos Group $1.82 / -0.065 (-3.45%) 05/15/23 Barclays Cronos Group price target lowered to $3 from $3.50 at Barclays 05/10/23 Canaccord Cronos Group price target lowered to C$4 from C$4.25 at Canaccord 03/01/23 Canaccord Cronos Group price target lowered to C$4.25 from C$4.75 at Canaccord CGC Canopy Growth $1.01 / -0.04 (-3.83%) 05/23/23 BofA Canopy risk of NASDAQ delisting eased by revised proxy, says BofA 05/02/23 Piper Sandler Canopy Growth price target lowered to $1 from $2 at Piper Sandler 05/01/23 BMO Capital Canopy Growth upgraded to Market Perform from Underperform at BMO Capital 04/04/23 Bernstein Canopy Growth upgraded to Market Perform from Underperform at Bernstein CVSI CV Sciences / + ACB Aurora Cannabis / + 02/13/23 CIBC Aurora Cannabis price target lowered to C$1.75 from C$2.25 at CIBC 02/10/23 Canaccord Aurora Cannabis price target lowered to C$1.50 from C$2 at Canaccord 02/10/23 Canaccord Aurora Cannabis price target lowered to C$1.50 from C$2.00 at Canaccord 01/27/23 Stifel Aurora Cannabis price target lowered to C$1.45 from C$1.75 at Stifel FISI Financial Institutions $16.43 / -0.18 (-1.08%) 10/31/22 Hovde Group Financial Institutions downgraded to Market Perform at Hovde Group SHFS SHF Holdings / + 10/26/22 EF Hutton SHF Holdings initiated with a Buy at EF Hutton ZYNE TLRY RLMD FISI CRON CMPS CGC ATAI ACB ZYNE Zynerba / + 05/15/23 Zynerba reports Q1 EPS (21c), consensus (19c) 03/28/23 Zynerba reports Q4 EPS (18c), consensus (18c) TLRY Tilray $2.37 / -0.045 (-1.87%) 04/10/23 Tilray reports Q3 EPS ($1.90) vs. 9c last year 01/09/23 Tilray reports Q2 adjusted EPS (6c) vs. (8c) last year RLMD Relmada Therapeutics $2.83 / -0.27 (-8.71%) 03/23/23 Relmada Therapeutics reports Q4 EPS ($1.28), consensus ($1.33) FISI Financial Institutions $16.43 / -0.18 (-1.08%) 04/26/23 Financial Institutions reports Q1 EPS 76c, consensus 81c 01/30/23 Financial Institutions reports Q4 EPS 76c, consensus 81c CRON Cronos Group $1.82 / -0.065 (-3.45%) 05/09/23 Cronos Group sees FY23 revenue $100M-$110M, consensus $102.93M 05/09/23 Cronos Group reports Q1 EPS (5c), consensus (5c) 02/28/23 Cronos Group reports Q3 EPS (21c), consensus (5c) CMPS Compass Pathways $7.60 / -0.29 (-3.68%) 05/11/23 Compass Pathways reports Q1 EPS (57c), consensus (68c) 02/28/23 Compass Pathways reports Q4 EPS (73c), consensus (59c) CGC Canopy Growth $1.01 / -0.04 (-3.83%) 04/06/23 Constellation Brands reports Q4 comparable EPS ex-Canopy $2.15 02/09/23 Canopy Growth reports Q3 EPS (C$0.54) vs. (C$0.28) a year ago ATAI Atai Life Sciences $1.80 / -0.02 (-1.10%) 05/11/23 Atai Life Sciences reports Q1 EPS (21c), consensus (21c) 03/24/23 Atai Life Sciences reports Q4 EPS (28c), consensus (23c) ACB Aurora Cannabis / + 02/09/23 Aurora Cannabis reports Q2 adjusted EBITDA C$1.4M vs. (C$7.1M) a year ago 02/09/23 Aurora Cannabis reports Q2 revenue C$61.7M vs. C$60.6M a year ago 27 May ZYNE TLRY CMPS ZYNE Zynerba / + 04/21/23 Booker says lawmakers to revive cannabis banking bill, Marijuana Moment says 12/27/22 FDA explores regulating CBD in foods, supplements, WSJ reports 12/05/22 Defense bill with marijuana reform attached is delayed, Marijuana Moment says TLRY Tilray $2.37 / -0.045 (-1.87%) 04/10/23 Tilray to buy Hexo in deal worth about $250M, Bloomberg says CMPS Compass Pathways $7.60 / -0.29 (-3.68%) 01/03/23 Oregon becomes first U.S. state to legalize 'magic' mushrooms, NYT says ZYNE RLMD CMPS ZYNE Zynerba / + 04/13/23 Here's What You Missed in Cannabis This Week RLMD Relmada Therapeutics $2.83 / -0.27 (-8.71%) 05/11/23 Here's What You Missed in Cannabis, Psychedelics This Week 05/04/23 Here's What You Missed in Cannabis This Week 04/20/23 Here's What You Missed in Cannabis This Week 03/30/23 Rising High: Exclusive talk with multinational cannabis operator Clever Leaves CMPS Compass Pathways $7.60 / -0.29 (-3.68%) 04/30/23 Short Report: Bears boost Vivid Seats position to record high as stock bottoms 05/25/23 Relmada Therapeutics, Inc. 06/14/23 Green Thumb Industries Inc. 06/21/23 Financial Institutions Inc 06/22/23 Cronos Group, Inc. TLRY CGC ACB TLRY Tilray $2.37 / -0.045 (-1.87%) 05/08/23 Largest borrow rate increases among liquid names 05/05/23 Unusually active option classes on open May 5th 04/28/23 Unusual call flow in option market yesterday 04/27/23 Cannabis stock implied volatilities move higher as sector climbs CGC Canopy Growth $1.01 / -0.04 (-3.83%) 05/16/23 Largest borrow rate increases among liquid names 03/07/23 Largest borrow rate increases among liquid names 03/01/23 Largest borrow rate increases among liquid names 02/27/23 Largest borrow rate increases among liquid names ACB Aurora Cannabis / + 05/24/23 Largest borrow rate increases among liquid names 05/23/23 Largest borrow rate increases among liquid names 05/22/23 Aurora Cannabis options imply 17.4% move in share price post-earnings 05/18/23 Aurora Cannabis options imply 11.0% move in share price post-earnings

Over a week ago
Conference/Events	Mizuho biotech analyst to hold an analyst/industry conference call » 09:50 05/24/23 05/24 09:50 05/24/23 09:50 ERAS Erasca $2.96 / -0.03 (-1.00%) , IMRX Immuneering $6.95 / + (+0.00%) , VSTM Verastem / + , MRK Merck $112.88 / -0.42 (-0.37%) , INCY Incyte $64.67 / -0.435 (-0.67%) , EFTR eFfector Therapeutics / + , LPTX Leap Therapeutics / + , RCUS Arcus Biosciences $17.94 / -0.14 (-0.77%) , CRVS Corvus Pharmaceuticals $3.00 / -0.09 (-2.91%) Biotechnology Analyst… Biotechnology Analyst Goldstein, along with Drs. Velcheti and Oberstein discuss targeted therapies in lung and GI cancer, (ERAS, IMRX, VSTM, MRK, INCY, EFTR, LPTX, RCUS, CRVS) as well as emerging trends and themes to be covered at the upcoming ASCO 2023 Annual Meeting on an Analyst/Industry conference call to be held on May 24 at 10 am. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options VSTM RCUS MRK LPTX INCY IMRX ERAS EFTR CRVS VSTM Verastem / + 04/26/23 Interim analysis of Verastem's RAMP 201 trial to be presented at ASCO 01/24/23 Verastem reports interim data from Part A of the ongoing RAMP 201 Phase 2 study RCUS Arcus Biosciences $17.94 / -0.14 (-0.77%) 05/15/23 Arcus Biosciences jumps 2% amid expanded inflammation pact with Gilead 05/15/23 Expanded Gilead- Arcus pact may result in up to $1B in payments to Arcus 05/15/23 Arcus to receive upfront payment of $35M from Gilead in expanded research pact 12/20/22 Arcus Biosciences falls -30.2% MRK Merck $112.88 / -0.42 (-0.37%) 05/17/23 Immutep announces results from Phse II TACTI-002 trial 05/16/23 Prometheus, Seagen slip after FTC sues to block Horizon acquisition 05/16/23 OncoSec reports Type C meeting with FDA for melanoma treatment 05/15/23 Canadian Solar subsidiary signs aggregation deal for 100MW in Texas LPTX Leap Therapeutics / + 04/12/23 Leap Therapeutics completes enrollment in Part A of DeFianCe study of DKN-01 03/16/23 Leap Therapeutics provides update on BeiGene option agreement for DKN-01 01/17/23 Leap Therapeutics acquires Flame Biosciences INCY Incyte $64.67 / -0.435 (-0.67%) 05/02/23 Incyte tightens Jakafi net product revenues view $2.55B - $2.63B 05/01/23 Incyte says SCRATCH-AD trial meets primary endpoint 04/20/23 Incyte reports EC approval of Opzelura for non-segmental vitiligo repigmentation 04/16/23 MorphoSys, Incyte announce five-year follow-up data from Phase 2 L-MIND study IMRX Immuneering $6.95 / + (+0.00%) 04/18/23 Immuneering down 5% at $11.53 after pricing $30M stock offering 04/18/23 Immuneering announces initial Phase 1 PK, PD, safety data for IMM-1-104 03/28/23 Immuneering appoints Harold Brakewood as CBO 03/05/23 Immuneering presents preclinical data with lead program IMM-1-104 ERAS Erasca $2.96 / -0.03 (-1.00%) 05/16/23 Erasca appoints Davd Chacko as CBO, Nik Chetwyn as COO 05/01/23 Erasca announces U.S. FDA granted FTD to ERAS-801 04/25/23 Erasca announces publication of clinical data on naporafenib 04/18/23 Erasca presents Phase 1b dose escalation data from FLAGSHIP-1 for ERAS-601 EFTR eFfector Therapeutics / + 04/11/23 eFfector Therapeutics to collaborate with Standford Medicine 02/21/23 eFfector announces top-line results from Phase 1b trial of zotatifin 01/05/23 eFfector Therapeutics provides clinical data update for Zotatifin CRVS Corvus Pharmaceuticals $3.00 / -0.09 (-2.91%) 05/17/23 Corvus Pharmaceuticals to present new CPI-818 data at ICML meeting 04/17/23 Corvus Pharmaceuticals presents new data for CPI-818 04/03/23 Corvus Pharmaceuticals announces interim data on CPI-818 02/21/23 Corvus Pharmaceuticals announces new data on CPI-818 ERAS IMRX VSTM MRK INCY EFTR LPTX RCUS CRVS ERAS Erasca $2.96 / -0.03 (-1.00%) 03/29/23 Mizuho Erasca initiated with a Buy at Mizuho 02/24/23 Goldman Sachs Erasca initiated with a Buy at Goldman Sachs 02/03/23 Morgan Stanley Erasca upgraded to Overweight from Equal Weight at Morgan Stanley IMRX Immuneering $6.95 / + (+0.00%) 04/19/23 Mizuho Immuneering upgraded to Buy from Neutral at Mizuho 04/19/23 Morgan Stanley Immuneering upgraded to Equal Weight from Underweight at Morgan Stanley 04/18/23 Chardan Immuneering price target raised to $22 from $18 at Chardan 03/29/23 Mizuho Immuneering initiated with a Neutral at Mizuho VSTM Verastem / + 05/10/23 H.C. Wainwright Verastem price target lowered to $2 from $3 at H.C. Wainwright 03/29/23 Mizuho Verastem initiated with a Neutral at Mizuho 11/07/22 H.C. Wainwright Verastem price target lowered to $3 from $5 at H.C. Wainwright 10/05/22 BTIG Verastem price target lowered to $5 from $8 at BTIG MRK Merck $112.88 / -0.42 (-0.37%) 05/10/23 Jefferies Prometheus downgraded to Hold from Buy at Jefferies 05/01/23 Barclays Merck price target raised to $130 from $128 at Barclays 04/18/23 Wells Fargo Prometheus downgraded to Equal Weight from Overweight at Wells Fargo 04/18/23 RBC Capital Prometheus downgraded to Sector Perform from Outperform at RBC Capital INCY Incyte $64.67 / -0.435 (-0.67%) 05/04/23 JMP Securities Incyte price target lowered to $93 from $113 at JMP Securities 05/04/23 BofA Incyte downgraded to Neutral at BofA on long-term value uncertainty 05/04/23 BofA Incyte downgraded to Neutral from Buy at BofA 05/03/23 BMO Capital Incyte price target lowered to $70 from $75 at BMO Capital EFTR eFfector Therapeutics / + LPTX Leap Therapeutics / + 03/17/23 Piper Sandler Leap Therapeutics news 'disappointing at first glance,' says Piper Sandler 03/17/23 Mizuho Leap Therapeutics price target lowered to $2 from $3 at Mizuho 01/27/23 Mizuho Leap Therapeutics price target lowered to $3 from $6 at Mizuho 01/17/23 Piper Sandler Leap Therapeutics price target lowered to $3 from $4 at Piper Sandler RCUS Arcus Biosciences $17.94 / -0.14 (-0.77%) 03/09/23 Citi Arcus Biosciences price target lowered to $40 from $42 at Citi 12/21/22 Citi Arcus Biosciences selloff a buying opportunity, says Citi 12/21/22 Barclays Arcus Biosciences price target lowered to $36 from $60 at Barclays 12/20/22 Citi Arcus Biosciences price target raised to $42 from $37 at Citi CRVS Corvus Pharmaceuticals $3.00 / -0.09 (-2.91%) 05/09/23 Cantor Fitzgerald Corvus Pharmaceuticals price target raised to $4 from $2 at Cantor Fitzgerald 10/07/22 Ladenburg Corvus Pharmaceuticals initiated with a Buy at Ladenburg 08/09/22 Cantor Fitzgerald Corvus Pharmaceuticals price target lowered to $4 from $8 at Cantor Fitzgerald VSTM RCUS MRK LPTX INCY ERAS EFTR CRVS VSTM Verastem / + 05/09/23 Verastem reports Q1 EPS (9c), consensus (8c) 03/14/23 Verastem reports Q4 EPS (8c), consensus (10c) RCUS Arcus Biosciences $17.94 / -0.14 (-0.77%) 05/09/23 Arcus Biosciences reports Q1 EPS ($1.09), consensus ($1.16) 02/28/23 Arcus Biosciences reports Q4 EPS (93c), consensus ($1.07) MRK Merck $112.88 / -0.42 (-0.37%) 04/27/23 Merck narrows FY23 revenue view to $57.7B-$58.9B from $57.2B-$58.7B 04/27/23 Merck reports Q1 adjusted EPS $1.40, consensus $1.32 04/26/23 Notable companies reporting before tomorrow's open LPTX Leap Therapeutics / + 05/15/23 Leap Therapeutics reports Q1 EPS (32c), consensus (10c) 03/24/23 Leap Therapeutics reports Q4 EPS (11c), consensus (11c) INCY Incyte $64.67 / -0.435 (-0.67%) 05/02/23 Incyte reports Q1 EPS 37c, consensus 75c 02/07/23 Incyte reports Q4 EPS 62c, consensus 58c 02/06/23 Notable companies reporting before tomorrow's open ERAS Erasca $2.96 / -0.03 (-1.00%) 05/15/23 Erasca reports Q1 EPS (22c), consensus (31c) 03/23/23 Erasca reports Q4 EPS ($1.06) vs. (26c) last year EFTR eFfector Therapeutics / + 05/09/23 eFfector Therapeutics reports Q1 EPS (24c), consensus (14c) 03/08/23 eFfector Therapeutics reports Q4 EPS (22c), consensus (24c) CRVS Corvus Pharmaceuticals $3.00 / -0.09 (-2.91%) 05/08/23 Corvus Pharmaceuticals reports Q1 EPS (17c), consensus (16c) 18 Apr 09 Dec MRK MRK Merck $112.88 / -0.42 (-0.37%) 02/27/23 Pfizer in talks to buy Seagen in deal that may be valued at over $30B, WSJ says 01/13/23 Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports 01/11/23 Merck, Pfizer rebuff China's efforts to cut Covid drug prices, Bloomberg says 12/30/22 Merck's Covid treatment gets conditional approval in China, Reuters reports VSTM RCUS MRK LPTX INCY ERAS VSTM Verastem / + 03/14/23 Fly Intel: After-Hours Movers RCUS Arcus Biosciences $17.94 / -0.14 (-0.77%) 12/20/22 What You Missed On Wall Street On Tuesday 12/20/22 What You Missed On Wall Street This Morning 12/19/22 Fly Intel: After-Hours Movers 11/30/22 Biotech Alert: Searches spiking for these stocks today MRK Merck $112.88 / -0.42 (-0.37%) 05/16/23 What You Missed On Wall Street On Tuesday 04/27/23 Fly Intel: Pre-market Movers 04/19/23 Biotech Alert: Searches spiking for these stocks today 04/17/23 What You Missed On Wall Street On Monday LPTX Leap Therapeutics / + 05/19/23 Biotech Alert: Searches spiking for these stocks today 03/24/23 What You Missed On Wall Street On Friday 03/24/23 What You Missed On Wall Street This Morning INCY Incyte $64.67 / -0.435 (-0.67%) 05/05/23 Biotech Alert: Searches spiking for these stocks today 05/04/23 Biotech Alert: Searches spiking for these stocks today 05/02/23 Fly Intel: Pre-market Movers 04/10/23 What You Missed On Wall Street On Monday ERAS Erasca $2.96 / -0.03 (-1.00%) 03/23/23 Fly Intel: After-Hours Movers 02/24/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/09/22 What You Missed On Wall Street On Friday 12/09/22 What You Missed On Wall Street This Morning 05/24/23 Biotechnology 06/02/23 Biotechnology--Pre-ASCO Reception 06/09/23 Biotechnology 06/12/23 Biotech/Biopharma 06/02/23 2023 ASCO Annual Meeting 11:00 Today Verastem - VSTM 08/01/23 Merck - MRK 05/24/23 Immuneering 06/14/23 Incyte Corporation 06/14/23 Immuneering Corp. 06/15/23 Arcus Biosciences, Inc. 06/15/23 Corvus Pharmaceuticals, Inc. 06/16/23 Leap Therapeutics, Inc. 06/22/23 Erasca, Inc. 06/22/23 eFFECTOR Therapeutics Inc MRK MRK Merck $112.88 / -0.42 (-0.37%) 04/25/23 Merck call volume above normal and directionally bullish 04/17/23 Unusually active option classes on open April 17th 03/10/23 Early notable gainers among liquid option names on March 10th 01/10/23 Largest borrow rate increases among liquid names
Conference/Events	Mizuho biotech analyst to hold an analyst/industry conference call » 04:55 05/24/23 05/24 04:55 05/24/23 04:55 ERAS Erasca $3.00 / +0.075 (+2.57%) , IMRX Immuneering $6.95 / -1.23 (-15.04%) , VSTM Verastem / + , MRK Merck $113.28 / -1.175 (-1.03%) , INCY Incyte $65.11 / +0.715 (+1.11%) , EFTR eFfector Therapeutics / + , LPTX Leap Therapeutics / + , RCUS Arcus Biosciences $18.06 / -0.08 (-0.44%) , CRVS Corvus Pharmaceuticals $3.09 / -0.28 (-8.31%) Biotechnology Analyst… Biotechnology Analyst Goldstein, along with Drs. Velcheti and Oberstein discuss targeted therapies in lung and GI cancer, (ERAS, IMRX, VSTM, MRK, INCY, EFTR, LPTX, RCUS, CRVS) as well as emerging trends and themes to be covered at the upcoming ASCO 2023 Annual Meeting on an Analyst/Industry conference call to be held on May 24 at 10 am. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options VSTM RCUS MRK LPTX INCY IMRX ERAS EFTR CRVS VSTM Verastem / + 04/26/23 Interim analysis of Verastem's RAMP 201 trial to be presented at ASCO 01/24/23 Verastem reports interim data from Part A of the ongoing RAMP 201 Phase 2 study RCUS Arcus Biosciences $18.06 / -0.08 (-0.44%) 05/15/23 Arcus Biosciences jumps 2% amid expanded inflammation pact with Gilead 05/15/23 Expanded Gilead- Arcus pact may result in up to $1B in payments to Arcus 05/15/23 Arcus to receive upfront payment of $35M from Gilead in expanded research pact 12/20/22 Arcus Biosciences falls -30.2% MRK Merck $113.28 / -1.175 (-1.03%) 05/17/23 Immutep announces results from Phse II TACTI-002 trial 05/16/23 Prometheus, Seagen slip after FTC sues to block Horizon acquisition 05/16/23 OncoSec reports Type C meeting with FDA for melanoma treatment 05/15/23 Canadian Solar subsidiary signs aggregation deal for 100MW in Texas LPTX Leap Therapeutics / + 04/12/23 Leap Therapeutics completes enrollment in Part A of DeFianCe study of DKN-01 03/16/23 Leap Therapeutics provides update on BeiGene option agreement for DKN-01 01/17/23 Leap Therapeutics acquires Flame Biosciences INCY Incyte $65.11 / +0.715 (+1.11%) 05/02/23 Incyte tightens Jakafi net product revenues view $2.55B - $2.63B 05/01/23 Incyte says SCRATCH-AD trial meets primary endpoint 04/20/23 Incyte reports EC approval of Opzelura for non-segmental vitiligo repigmentation 04/16/23 MorphoSys, Incyte announce five-year follow-up data from Phase 2 L-MIND study IMRX Immuneering $6.95 / -1.23 (-15.04%) 04/18/23 Immuneering down 5% at $11.53 after pricing $30M stock offering 04/18/23 Immuneering announces initial Phase 1 PK, PD, safety data for IMM-1-104 03/28/23 Immuneering appoints Harold Brakewood as CBO 03/05/23 Immuneering presents preclinical data with lead program IMM-1-104 ERAS Erasca $3.00 / +0.075 (+2.57%) 05/16/23 Erasca appoints Davd Chacko as CBO, Nik Chetwyn as COO 05/01/23 Erasca announces U.S. FDA granted FTD to ERAS-801 04/25/23 Erasca announces publication of clinical data on naporafenib 04/18/23 Erasca presents Phase 1b dose escalation data from FLAGSHIP-1 for ERAS-601 EFTR eFfector Therapeutics / + 04/11/23 eFfector Therapeutics to collaborate with Standford Medicine 02/21/23 eFfector announces top-line results from Phase 1b trial of zotatifin 01/05/23 eFfector Therapeutics provides clinical data update for Zotatifin CRVS Corvus Pharmaceuticals $3.09 / -0.28 (-8.31%) 05/17/23 Corvus Pharmaceuticals to present new CPI-818 data at ICML meeting 04/17/23 Corvus Pharmaceuticals presents new data for CPI-818 04/03/23 Corvus Pharmaceuticals announces interim data on CPI-818 02/21/23 Corvus Pharmaceuticals announces new data on CPI-818 ERAS IMRX VSTM MRK INCY EFTR LPTX RCUS CRVS ERAS Erasca $3.00 / +0.075 (+2.57%) 03/29/23 Mizuho Erasca initiated with a Buy at Mizuho 02/24/23 Goldman Sachs Erasca initiated with a Buy at Goldman Sachs 02/03/23 Morgan Stanley Erasca upgraded to Overweight from Equal Weight at Morgan Stanley IMRX Immuneering $6.95 / -1.23 (-15.04%) 04/19/23 Mizuho Immuneering upgraded to Buy from Neutral at Mizuho 04/19/23 Morgan Stanley Immuneering upgraded to Equal Weight from Underweight at Morgan Stanley 04/18/23 Chardan Immuneering price target raised to $22 from $18 at Chardan 03/29/23 Mizuho Immuneering initiated with a Neutral at Mizuho VSTM Verastem / + 05/10/23 H.C. Wainwright Verastem price target lowered to $2 from $3 at H.C. Wainwright 03/29/23 Mizuho Verastem initiated with a Neutral at Mizuho 11/07/22 H.C. Wainwright Verastem price target lowered to $3 from $5 at H.C. Wainwright 10/05/22 BTIG Verastem price target lowered to $5 from $8 at BTIG MRK Merck $113.28 / -1.175 (-1.03%) 05/10/23 Jefferies Prometheus downgraded to Hold from Buy at Jefferies 05/01/23 Barclays Merck price target raised to $130 from $128 at Barclays 04/18/23 Wells Fargo Prometheus downgraded to Equal Weight from Overweight at Wells Fargo 04/18/23 RBC Capital Prometheus downgraded to Sector Perform from Outperform at RBC Capital INCY Incyte $65.11 / +0.715 (+1.11%) 05/04/23 JMP Securities Incyte price target lowered to $93 from $113 at JMP Securities 05/04/23 BofA Incyte downgraded to Neutral at BofA on long-term value uncertainty 05/04/23 BofA Incyte downgraded to Neutral from Buy at BofA 05/03/23 BMO Capital Incyte price target lowered to $70 from $75 at BMO Capital EFTR eFfector Therapeutics / + LPTX Leap Therapeutics / + 03/17/23 Piper Sandler Leap Therapeutics news 'disappointing at first glance,' says Piper Sandler 03/17/23 Mizuho Leap Therapeutics price target lowered to $2 from $3 at Mizuho 01/27/23 Mizuho Leap Therapeutics price target lowered to $3 from $6 at Mizuho 01/17/23 Piper Sandler Leap Therapeutics price target lowered to $3 from $4 at Piper Sandler RCUS Arcus Biosciences $18.06 / -0.08 (-0.44%) 03/09/23 Citi Arcus Biosciences price target lowered to $40 from $42 at Citi 12/21/22 Citi Arcus Biosciences selloff a buying opportunity, says Citi 12/21/22 Barclays Arcus Biosciences price target lowered to $36 from $60 at Barclays 12/20/22 Citi Arcus Biosciences price target raised to $42 from $37 at Citi CRVS Corvus Pharmaceuticals $3.09 / -0.28 (-8.31%) 05/09/23 Cantor Fitzgerald Corvus Pharmaceuticals price target raised to $4 from $2 at Cantor Fitzgerald 10/07/22 Ladenburg Corvus Pharmaceuticals initiated with a Buy at Ladenburg 08/09/22 Cantor Fitzgerald Corvus Pharmaceuticals price target lowered to $4 from $8 at Cantor Fitzgerald VSTM RCUS MRK LPTX INCY ERAS EFTR CRVS VSTM Verastem / + 05/09/23 Verastem reports Q1 EPS (9c), consensus (8c) 03/14/23 Verastem reports Q4 EPS (8c), consensus (10c) RCUS Arcus Biosciences $18.06 / -0.08 (-0.44%) 05/09/23 Arcus Biosciences reports Q1 EPS ($1.09), consensus ($1.16) 02/28/23 Arcus Biosciences reports Q4 EPS (93c), consensus ($1.07) MRK Merck $113.28 / -1.175 (-1.03%) 04/27/23 Merck narrows FY23 revenue view to $57.7B-$58.9B from $57.2B-$58.7B 04/27/23 Merck reports Q1 adjusted EPS $1.40, consensus $1.32 04/26/23 Notable companies reporting before tomorrow's open LPTX Leap Therapeutics / + 05/15/23 Leap Therapeutics reports Q1 EPS (32c), consensus (10c) 03/24/23 Leap Therapeutics reports Q4 EPS (11c), consensus (11c) INCY Incyte $65.11 / +0.715 (+1.11%) 05/02/23 Incyte reports Q1 EPS 37c, consensus 75c 02/07/23 Incyte reports Q4 EPS 62c, consensus 58c 02/06/23 Notable companies reporting before tomorrow's open ERAS Erasca $3.00 / +0.075 (+2.57%) 05/15/23 Erasca reports Q1 EPS (22c), consensus (31c) 03/23/23 Erasca reports Q4 EPS ($1.06) vs. (26c) last year EFTR eFfector Therapeutics / + 05/09/23 eFfector Therapeutics reports Q1 EPS (24c), consensus (14c) 03/08/23 eFfector Therapeutics reports Q4 EPS (22c), consensus (24c) CRVS Corvus Pharmaceuticals $3.09 / -0.28 (-8.31%) 05/08/23 Corvus Pharmaceuticals reports Q1 EPS (17c), consensus (16c) 18 Apr 09 Dec MRK MRK Merck $113.28 / -1.175 (-1.03%) 02/27/23 Pfizer in talks to buy Seagen in deal that may be valued at over $30B, WSJ says 01/13/23 Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports 01/11/23 Merck, Pfizer rebuff China's efforts to cut Covid drug prices, Bloomberg says 12/30/22 Merck's Covid treatment gets conditional approval in China, Reuters reports VSTM RCUS MRK LPTX INCY ERAS VSTM Verastem / + 03/14/23 Fly Intel: After-Hours Movers RCUS Arcus Biosciences $18.06 / -0.08 (-0.44%) 12/20/22 What You Missed On Wall Street On Tuesday 12/20/22 What You Missed On Wall Street This Morning 12/19/22 Fly Intel: After-Hours Movers 11/30/22 Biotech Alert: Searches spiking for these stocks today MRK Merck $113.28 / -1.175 (-1.03%) 05/16/23 What You Missed On Wall Street On Tuesday 04/27/23 Fly Intel: Pre-market Movers 04/19/23 Biotech Alert: Searches spiking for these stocks today 04/17/23 What You Missed On Wall Street On Monday LPTX Leap Therapeutics / + 05/19/23 Biotech Alert: Searches spiking for these stocks today 03/24/23 What You Missed On Wall Street On Friday 03/24/23 What You Missed On Wall Street This Morning INCY Incyte $65.11 / +0.715 (+1.11%) 05/05/23 Biotech Alert: Searches spiking for these stocks today 05/04/23 Biotech Alert: Searches spiking for these stocks today 05/02/23 Fly Intel: Pre-market Movers 04/10/23 What You Missed On Wall Street On Monday ERAS Erasca $3.00 / +0.075 (+2.57%) 03/23/23 Fly Intel: After-Hours Movers 02/24/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/09/22 What You Missed On Wall Street On Friday 12/09/22 What You Missed On Wall Street This Morning 05/24/23 Biotechnology 06/02/23 Biotechnology--Pre-ASCO Reception 06/09/23 Biotechnology 06/12/23 Biotech/Biopharma 06/02/23 2023 ASCO Annual Meeting 11:00 Today Verastem - VSTM 08/01/23 Merck - MRK 05/24/23 Immuneering 06/14/23 Incyte Corporation 06/14/23 Immuneering Corp. 06/15/23 Arcus Biosciences, Inc. 06/15/23 Corvus Pharmaceuticals, Inc. 06/16/23 Leap Therapeutics, Inc. 06/22/23 Erasca, Inc. 06/22/23 eFFECTOR Therapeutics Inc MRK MRK Merck $113.28 / -1.175 (-1.03%) 04/25/23 Merck call volume above normal and directionally bullish 04/17/23 Unusually active option classes on open April 17th 03/10/23 Early notable gainers among liquid option names on March 10th 01/10/23 Largest borrow rate increases among liquid names
Hot Stocks	Ouster rises 16.6% » 12:00 05/22/23 05/22 12:00 05/22/23 12:00 OUST Ouster $5.97 / +0.87 (+17.06%) Ouster is up 16.6%, or… Ouster is up 16.6%, or 85c to $5.96. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events OUST Ouster $5.97 / +0.87 (+17.06%) 05/19/23 Ouster rises 8.1% 05/18/23 Ouster: ITC votes to investigate unfair trade practices of Hesai 05/17/23 Ouster falls -8.1% 05/16/23 Ouster expands supply agreements with May Mobility's OUST Ouster $5.97 / +0.87 (+17.06%) 05/12/23 Craig-Hallum Ouster price target lowered to $10 from $15 at Craig-Hallum 04/02/23 Citi Ouster price target lowered to $1 from $1.70 at Citi 03/24/23 Chardan Ouster downgraded to Neutral from Buy at Chardan 03/24/23 Cantor Fitzgerald Ouster price target lowered to $3 from $5 at Cantor Fitzgerald OUST Ouster $5.97 / +0.87 (+17.06%) 05/11/23 Ouster reports Q1 EPS ($6.03), consensus ($2.20) 03/23/23 Ouster sees Q1 revenue $15M-$17M, consensus $20.1M 03/23/23 Ouster reports Q4 EPS (23c), consensus (18c) OUST Ouster $5.97 / +0.87 (+17.06%) 05/18/23 Fly Intel: After-Hours Movers 03/24/23 Fly Intel: Pre-market Movers 03/23/23 Fly Intel: After-Hours Movers 06/22/23 Ouster Inc
Hot Stocks	Athira Pharma appoints Gengos as CFO, CBO » 07:18 05/22/23 05/22 07:18 05/22/23 07:18 ATHA Athira Pharma $2.89 / +0.045 (+1.58%) , CYT Cyteir Therapeutics $2.21 / +0.01 (+0.45%) Athira Pharma (ATHA)… Athira Pharma (ATHA) announced the appointment of Andrew Gengos as Chief Financial Officer, CFO, and Chief Business Officer, CBO, effective immediately. Gengos replaces Glenna Mileson, who is retiring after serving as Athira's Chief Financial Officer for eight years. Most recently, Gengos served as the Chief Business Officer at Cyteir Therapeutics (CYT), where he was an integral part of the leadership team that took the company public. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events CYT ATHA CYT Cyteir Therapeutics $2.21 / +0.01 (+0.45%) 02/06/23 Cyteir Therapeutics promotes David Gaiero to CFO 01/19/23 Cyteir Therapeutics announces prioritization of CYT-0851 development ATHA Athira Pharma $2.89 / +0.045 (+1.58%) 05/22/23 Correction: Athira Pharma did not report Scientific Advisory appointments 05/22/23 Athira Pharma appoints Croft, Edelson to SAB 03/28/23 Athira Pharma presents preclinical data about fosgonimeton at AD/PD 2023 02/01/23 Athira announces publication on need for novel Alzheimer's disease treatment ATHA CYT ATHA Athira Pharma $2.89 / +0.045 (+1.58%) 05/15/23 Mizuho Athira Pharma price target lowered to $5 from $6 at Mizuho 03/30/23 BTIG Athira Pharma price target lowered to $10 from $33 at BTIG 10/17/22 JMP Securities Athira upgraded to Outperform at JMP after DMC recommends study continue 10/17/22 JMP Securities Athira Pharma upgraded to Outperform from Market Perform at JMP Securities CYT Cyteir Therapeutics $2.21 / +0.01 (+0.45%) 02/03/23 Morgan Stanley Cyteir downgraded to Underweight from Equal Weight at Morgan Stanley 01/30/23 BofA Cyteir Therapeutics downgraded to Neutral at BofA after strategic prioritization 01/30/23 BofA Cyteir Therapeutics downgraded to Neutral from Buy at BofA 01/20/23 JPMorgan Cyteir Therapeutics downgraded to Neutral from Overweight at JPMorgan CYT ATHA CYT Cyteir Therapeutics $2.21 / +0.01 (+0.45%) 05/10/23 Cyteir Therapeutics reports Q1 EPS (35c), consensus (27c) 03/23/23 Cyteir Therapeutics reports Q4 EPS (25c), consensus (34c) ATHA Athira Pharma $2.89 / +0.045 (+1.58%) 05/11/23 Athira Pharma reports Q1 EPS (73c), consensus (62c) CYT ATHA CYT Cyteir Therapeutics $2.21 / +0.01 (+0.45%) 03/23/23 Fly Intel: After-Hours Movers ATHA Athira Pharma $2.89 / +0.045 (+1.58%) 01/03/23 Fly Insider: Terns Pharma, Best Buy among week's notable insider trades 06/14/23 Cyteir Therapeutics, Inc.
Hot Stocks	Ouster rises 8.1% » 09:47 05/19/23 05/19 09:47 05/19/23 09:47 OUST Ouster $5.88 / +0.485 (+8.99%) Ouster is up 8.1%, or 44c… Ouster is up 8.1%, or 44c to $5.84. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events OUST Ouster $5.88 / +0.485 (+8.99%) 05/18/23 Ouster: ITC votes to investigate unfair trade practices of Hesai 05/17/23 Ouster falls -8.1% 05/16/23 Ouster expands supply agreements with May Mobility's 05/12/23 Ouster rises 19.5% OUST Ouster $5.88 / +0.485 (+8.99%) 05/12/23 Craig-Hallum Ouster price target lowered to $10 from $15 at Craig-Hallum 04/02/23 Citi Ouster price target lowered to $1 from $1.70 at Citi 03/24/23 Chardan Ouster downgraded to Neutral from Buy at Chardan 03/24/23 Cantor Fitzgerald Ouster price target lowered to $3 from $5 at Cantor Fitzgerald OUST Ouster $5.88 / +0.485 (+8.99%) 05/11/23 Ouster reports Q1 EPS ($6.03), consensus ($2.20) 03/23/23 Ouster sees Q1 revenue $15M-$17M, consensus $20.1M 03/23/23 Ouster reports Q4 EPS (23c), consensus (18c) OUST Ouster $5.88 / +0.485 (+8.99%) 05/18/23 Fly Intel: After-Hours Movers 03/24/23 Fly Intel: Pre-market Movers 03/23/23 Fly Intel: After-Hours Movers 06/22/23 Ouster Inc
On The Fly	Fly Intel: After-Hours Movers » 18:25 05/18/23 05/18 18:25 05/18/23 18:25 FTCH Farfetch $4.35 / +0.26 (+6.36%) , GLOB Globant $151.67 / +1.265 (+0.84%) , OUST Ouster $5.40 / -0.3 (-5.27%) , FLO Flowers Foods $28.85 / +0.21 (+0.73%) , DXC DXC Technology $23.84 / +0.085 (+0.36%) , CVCO Cavco Industries $294.31 / +0.38 (+0.13%) , AMAT Applied Materials $129.93 / +4.29 (+3.41%) Check out this evening's… Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options OUST GLOB FTCH FLO DXC CVCO AMAT OUST Ouster $5.40 / -0.3 (-5.27%) 05/18/23 Ouster: ITC votes to investigate unfair trade practices of Hesai 05/17/23 Ouster falls -8.1% 05/16/23 Ouster expands supply agreements with May Mobility's 05/12/23 Ouster rises 19.5% GLOB Globant $151.67 / +1.265 (+0.84%) 05/15/23 Globant to acquire Pentalog, terms undisclosed 04/24/23 Globant acquires ExperienceIT; financial terms not disclosed 04/12/23 Globant Ventures invests in SaaS financial industry platform Fivvy 03/30/23 Globant expands global partnership with Google Cloud FTCH Farfetch $4.35 / +0.26 (+6.36%) 05/18/23 Farfetch jumps 17% to $5.09 after Q1 earnings beat, affirmed guidance 03/24/23 Farfetch falls -8.1% 02/24/23 Farfetch rises 13.0% 02/23/23 Farfetch CFO Jordan to step down by end of 2023 FLO Flowers Foods $28.85 / +0.21 (+0.73%) 03/07/23 Flowers Foods elects A. Ryals McMullian as the next chairman of the board 02/06/23 Flowers Foods names Cindy Cox as chief human resources officer 12/13/22 Flowers Foods to acquire Papa Pita Bakery DXC DXC Technology $23.84 / +0.085 (+0.36%) 05/18/23 DXC Technology names Rob Del Bene as new CFO 05/03/23 Ferrari signs partnership agreement with DXC Technology 05/03/23 DXC Technology signs agreement with Scuderia Ferrari 03/14/23 SEC charges DXC Technology with making misleading disclosures CVCO Cavco Industries $294.31 / +0.38 (+0.13%) 01/17/23 Cavco Industries launches new affordable home digital marketplace AMAT Applied Materials $129.93 / +4.29 (+3.41%) 05/18/23 Applied Materials says capex to be higher over next several years 05/15/23 Tiger Global buys TSMC, exits AppLovin in Q1 03/22/23 Applied Materials exec sells $3.67M in common stock 03/13/23 Applied Materials board approves $10B share repurchase authorization FTCH GLOB OUST FLO DXC CVCO AMAT FTCH Farfetch $4.35 / +0.26 (+6.36%) 03/24/23 Citi Farfetch price target lowered to $4 from $6 at Citi 03/24/23 JMP Securities Farfetch initiated with a Market Perform at JMP Securities 01/30/23 KeyBanc KeyBanc keeps Overweight on Farfetch, lowers price target to $11 12/15/22 Oppenheimer Farfetch price target lowered to $7 from $14 at Oppenheimer GLOB Globant $151.67 / +1.265 (+0.84%) 05/16/23 TD Cowen Globant price target lowered to $177 from $187 at TD Cowen 05/01/23 Citi Citi lowers Globant target, opens 'positive catalyst watch' 04/12/23 Needham Needham starts Globant with Buy on 'best-in-breed' organic growth OUST Ouster $5.40 / -0.3 (-5.27%) 05/12/23 Craig-Hallum Ouster price target lowered to $10 from $15 at Craig-Hallum 04/02/23 Citi Ouster price target lowered to $1 from $1.70 at Citi 03/24/23 Chardan Ouster downgraded to Neutral from Buy at Chardan 03/24/23 Cantor Fitzgerald Ouster price target lowered to $3 from $5 at Cantor Fitzgerald FLO Flowers Foods $28.85 / +0.21 (+0.73%) 03/20/23 Deutsche Bank Flowers Foods price target lowered to $26 from $27 at Deutsche Bank 03/03/23 Deutsche Bank Flowers Foods upgraded to Hold from Sell at Deutsche Bank 12/06/22 Deutsche Bank Flowers Foods downgraded to Sell from Hold at Deutsche Bank 05/23/22 Deutsche Bank Flowers Foods price target lowered to $26 from $27 at Deutsche Bank DXC DXC Technology $23.84 / +0.085 (+0.36%) 02/02/23 Deutsche Bank DXC Technology price target lowered to $35 from $48 at Deutsche Bank 01/19/23 MoffettNathanson DXC Technology downgraded to Underperform at MoffettNathanson 12/15/22 JPMorgan DXC Technology upgraded to Neutral from Underweight at JPMorgan 10/14/22 JPMorgan DXC Technology price target lowered to $31 from $33 at JPMorgan CVCO Cavco Industries $294.31 / +0.38 (+0.13%) 04/24/23 Craig-Hallum Cavco Industries price target raised to $357 from $310 at Craig-Hallum 02/06/23 Wedbush Cavco Industries price target raised to $410 from $385 at Wedbush 12/30/22 Wedbush Wedbush favors four homebuilding stocks heading into 2023 11/07/22 Craig-Hallum Cavco Industries price target lowered to $290 from $335 at Craig-Hallum AMAT Applied Materials $129.93 / +4.29 (+3.41%) 04/06/23 Exane BNP Paribas Applied Materials downgraded to Neutral from Outperform at Exane BNP Paribas 03/09/23 Citi Citi says HDD storage prices ticking up 03/01/23 KGI Securities Applied Materials upgraded to Outperform from Neutral at KGI Securities 02/24/23 TD Cowen Applied Materials price target lowered to $271 from $279 at Cowen OUST GLOB FTCH FLO DXC CVCO AMAT OUST Ouster $5.40 / -0.3 (-5.27%) 05/11/23 Ouster reports Q1 EPS ($6.03), consensus ($2.20) 03/23/23 Ouster sees Q1 revenue $15M-$17M, consensus $20.1M 03/23/23 Ouster reports Q4 EPS (23c), consensus (18c) GLOB Globant $151.67 / +1.265 (+0.84%) 05/18/23 Globant sees 2023 adjusted EPS at least $5.71, consensus $5.70 05/18/23 Globant sees Q2 EPS at least $1.33, consensus 41.35 05/18/23 Globant reports Q1 adjusted EPS 84c, consensus $1.27 02/16/23 Globant sees FY23 non-IFRS adjusted EPS at least $5.70, consensus $5.99 FTCH Farfetch $4.35 / +0.26 (+6.36%) 05/18/23 Farfetch backs FY23 adjusted EBITDA margin view 1%-3% 05/18/23 Farfetch reports Q1 adjusted EPS (16c), consensus (42c) 02/23/23 Farfetch sees FY23 adjusted EBITDA margin 1%-3% 02/23/23 Farfetch reports Q4 adjusted EPS (25c), consensus (47c) FLO Flowers Foods $28.85 / +0.21 (+0.73%) 05/18/23 Flowers Foods cuts FY23 adjusted EPS view to $1.15-$1.25 from $1.20-$1.30 05/18/23 Flowers Foods reports Q1 adjusted EPS 38c, consensus 38c 02/09/23 Flowers Foods sees 2023 adjusted EPS $1.2-$1.30, consensus $1.33 02/09/23 Flowers Foods reports Q4 adjusted EPS 23c, consensus 23c DXC DXC Technology $23.84 / +0.085 (+0.36%) 05/18/23 DXC Technology sees FY24 adjusted EPS $3.80-$4.05, consensus $3.98 05/18/23 DXC Technology sees Q1 adjusted EPS 80c-85c, consensus 92c 05/18/23 DXC Technology reports Q4 adjusted EPS $1.02, consensus $1.03 05/18/23 Notable companies reporting after market close CVCO Cavco Industries $294.31 / +0.38 (+0.13%) 05/18/23 Cavco Industries reports Q4 EPS $5.39, consensus $5.10 02/02/23 Cavco Industries reports Q3 EPS $6.66, consensus $5.79 AMAT Applied Materials $129.93 / +4.29 (+3.41%) 05/18/23 Applied Materials sees Q3 adjusted EPS $1.56-$1.92, consensus $1.65 05/18/23 Applied Materials reports Q2 adjusted EPS $2.00, consensus $1.84 02/16/23 Applied Materials sees Q2 EPS $1.66-$2.02, consensus $1.75 FTCH AMAT FTCH Farfetch $4.35 / +0.26 (+6.36%) 12/21/22 RealReal could be market consolidator as resale ripe for M&A, Axios says AMAT Applied Materials $129.93 / +4.29 (+3.41%) 03/10/23 U.S. to further tighten chip gear export to China restrictions, Bloomberg says 03/10/23 U.S. to further tighten chip gear export to China restrictions, Bloomberg says OUST FTCH FLO DXC AMAT OUST Ouster $5.40 / -0.3 (-5.27%) 03/24/23 Fly Intel: Pre-market Movers 03/23/23 Fly Intel: After-Hours Movers FTCH Farfetch $4.35 / +0.26 (+6.36%) 03/24/23 What You Missed On Wall Street On Friday 03/24/23 What You Missed On Wall Street This Morning 03/24/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/24/23 What You Missed On Wall Street On Friday FLO Flowers Foods $28.85 / +0.21 (+0.73%) 12/06/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations DXC DXC Technology $23.84 / +0.085 (+0.36%) 03/06/23 Fly Intel: After-Hours Movers 01/21/23 Buy/Sell: Wall Street's top 10 stock calls this week 01/19/23 What You Missed On Wall Street On Thursday 01/19/23 What You Missed On Wall Street This Morning AMAT Applied Materials $129.93 / +4.29 (+3.41%) 02/17/23 What You Missed On Wall Street On Friday 02/17/23 What You Missed On Wall Street This Morning 02/16/23 Fly Intel: After-Hours Movers 12/07/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/18/23 Farfetch - FTCH 05/18/23 Applied Materials - AMAT 05/18/23 Globant - GLOB 05/18/23 DXC Technology - DXC 05/19/23 Flowers Foods - FLO 05/19/23 Cavco Industries - CVCO 05/23/23 Globant 05/25/23 Flowers Foods, Inc. 06/22/23 Ouster Inc 06/27/23 Cavco Industries FTCH DXC AMAT FTCH Farfetch $4.35 / +0.26 (+6.36%) 05/18/23 Farfetch Limited options imply 13.7% move in share price post-earnings 04/24/23 Unusually active option classes on open April 24th 04/21/23 Unusually active option classes on open April 21st 03/06/23 Farfetch Limited call volume above normal and directionally bullish DXC DXC Technology $23.84 / +0.085 (+0.36%) 05/18/23 DXC Technology options imply 5.2% move in share price post-earnings 02/01/23 DXC Technology options imply 7.5% move in share price post-earnings AMAT Applied Materials $129.93 / +4.29 (+3.41%) 05/18/23 Applied Materials options imply 3.3% move in share price post-earnings 04/20/23 Early notable gainers among liquid option names on April 20th 03/29/23 Unusually active option classes on open March 29th 02/28/23 Early notable gainers among liquid option names on February 28th

On The Fly

News and insights, exclusive to thefly.com

12:00	Here's what Wall Street experts are saying about Salesforce ahead of earnings»
11:58	What You Missed On Wall Street This Morning»
09:41	Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations»
08:58	Fly Intel: Pre-market Movers»
19:03	Fly Intel: After-Hours Movers»

View all On The Fly Stories »

Upcoming
Events (10)

POWI ...	51st Annual Technology, Media & Telecom Conference
	ESG Virtual Summit
	5th Annual Auto Technology Conference 2023
WIX ...	Software Conference
ESMT ...	20th Annual Institutional Investor Conference
CWST ...	Industrials & Basic Materials Conference
NVST ...	2023 Jaws and Paws Conference
	4th Annual Oncology Innovation Summit: Insights for ASCO & EHA
DDOG	Datadog
PRA	ProAssurance

View all of today’s events »

Today’s
Syndicate (3)

ASLE	Spot Secondary
BLTE	Spot Secondary
HRZN	Spot Secondary

View this week’s syndicate »

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial